GLP-1 Obesity Drugs Seize 25% of Pharma Pipeline, Overtaking Oncology After 16 Years
Updated
Updated · Fox Business · Aug 20
GLP-1 Obesity Drugs Seize 25% of Pharma Pipeline, Overtaking Oncology After 16 Years
3 articles · Updated · Fox Business · Aug 20
Summary
Obesity drugs now make up about 25% of the late-stage pharmaceutical pipeline, Wells Fargo said, surpassing oncology at 20% for the first time in 16 years.
GLP-1 therapies drove nearly all of that shift, lifting obesity treatments from 1% of the pipeline in 2022 as drug use jumped more than 140% from 2022 to 2024.
That uptake is already changing care delivery: bariatric surgery volumes fell 34.1% in the same period as patients gained a visible, reversible alternative to surgery.
A 20% reduction in major cardiovascular events seen in overweight or obese adults without diabetes suggests broader pressure on hospital revenue tied to procedures, readmissions and complications.
Wells Fargo said likely healthcare winners will reallocate capital and staff toward obesity medicine, integrated cardiometabolic care and specialty pharmacy rather than defend the old model.